Consolidated loss narrows to ₹50.8 Cr; standalone PAT jumps 96% as US drag persists
PAT +21.1% YoY · revenue +41.03% · margins expanding
₹697.72 Cr
+41.03% YoY
₹-50.77 Cr
+21.1% YoY
-7.25%
+5.7pp YoY
₹-23.03
Sundaram-Clayton's consolidated net loss narrowed to ₹50.8 Cr in Q2 FY27 from ₹64.4 Cr a year ago and ₹59.3 Cr last quarter, as revenue grew 41% YoY (18% QoQ) to ₹697.7 Cr. On a standalone basis — which excludes the loss-making US operations — the print was far stronger: revenue grew 37% YoY to ₹629.4 Cr and PAT nearly doubled to ₹39.5 Cr from ₹20.2 Cr, taking EPS to ₹17.91 from ₹9.16. The divergence is the story: India operations are solidly profitable and accelerating, while the US subsidiary continues to post losses large enough to pull the consolidated book into the red.
Q2 FY-2027 vs prior quarters
Consolidated NPM improved to -7.3% from -12.9% a year ago and -10.0% last quarter, confirming the loss is narrowing on an operating basis and not just at the net line. On the standalone book, management's own numbers show EBITDA of ₹98.9 Cr at a 15.7% margin, up from ₹79.1 Cr in absolute terms but down from a 17.1% margin a year ago — alloy, energy and logistics cost pressure diluted the margin even as volumes and PAT grew; the bottom line was helped by lower finance costs (₹16.6 Cr vs ₹19.9 Cr) even as the effective tax rate rose. Per the auditor's review note, the unreviewed US entities alone carried a net loss of ₹90.5 Cr on revenue of ₹83.1 Cr for the quarter, underscoring that the US business remains the primary drag on the consolidated result even as "production at the US facility continued to ramp up," per the company.
The stock went into the print at ₹1,181.5, up 0.8% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
No prior management guidance or concall commentary is on record for this quarter, and no sell-side consensus estimates for Q2 FY27 could be located, so vsGuidance and vsStreet are both unknown. There were no exceptional items in either the current or year-ago quarter (unlike Q4 FY26, which carried a ₹521.2 Cr asset-sale gain), so the YoY comparison is clean. Demand tailwinds cited by management include M&HCV volumes up 23% YoY in H1 (33% in Q2, aided by pre-buying ahead of an October price hike) and passenger-vehicle volumes up 24% YoY on GST 2.0-aided affordability; in the US, Class 8 retail sales rose 10% YoY in Q3 CY2026 with production up 53%, which management frames as an improving backdrop for the ramping US facility. Separately, the board approved raising up to ₹700 Cr via NCDs/other borrowings, a balance-sheet action concurrent with the results but not yet reflected in this quarter's numbers.
W1
Pace of US loss-narrowing — unreviewed US entities lost ₹90.5 Cr this quarter; watch whether restructuring narrows this further next quarter
W2
Standalone EBITDA margin trajectory — fell to 15.7% from 17.1% YoY on input costs; watch if alloy/energy/logistics pressure eases
W3
Use of the ₹700 Cr NCD/borrowing approval — watch for actual issuance size and stated purpose (capex vs refinancing)